140 related articles for article (PubMed ID: 1592361)
1. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
Robert J; Rigal-Huguet F; Hurteloup P
Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Tidefelt U; Sundman-Engberg B; Paul C
Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
[TBL] [Abstract][Full Text] [Related]
5. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
[TBL] [Abstract][Full Text] [Related]
8. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
10. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of idarubicin.
Robert J
Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
[TBL] [Abstract][Full Text] [Related]
12. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
Hempel G; Haberland S; Schulze-Westhoff P; Möhling N; Blaschke G; Boos J
J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):287-92. PubMed ID: 9367219
[TBL] [Abstract][Full Text] [Related]
13. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
Fujita H; Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1992 Jun; 19(6):791-8. PubMed ID: 1605655
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Looby M; Linke R; Weiss M
Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
Elbaek K; Ebbehøj E; Jakobsen A; Juul P; Rasmussen SN; Bastholt L; Dalmark M; Steiness E
Clin Pharmacol Ther; 1989 Jun; 45(6):627-34. PubMed ID: 2731405
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability and pharmacology of oral idarubicin.
Stewart DJ; Grewaal D; Green RM; Verma S; Maroun JA; Redmond D; Robillard L; Gupta S
Cancer Chemother Pharmacol; 1991; 27(4):308-14. PubMed ID: 1998987
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]